Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...
Dutch biopharma Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer. Bizengri (zenocutuzumab) targets the ...
Merus Shares Are Up Today: What's Going On? Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted ...
Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.
Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal ...
Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative ...
In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m ...
One thing we could say about the analysts on Merus N.V. (NASDAQ:MRUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results